A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4635 in Japanese Patients With Advanced Solid Malignancies
- Conditions
- Advanced Solid Malignancies
- Registration Number
- JPRN-jRCT2080224739
- Lead Sponsor
- AstraZeneca KK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 12
Adult subjects; age 20 years or more
- Histologically or cytological confirmation of a solid, malignant tumor, excluding central nervous system (CNS) tumors and lymphoma, that is refractory to standard therapy or for which no standard of care regimen currently exists
- Patients must have either at least one lesion that can be evaluable using RECIST v1.1 or patients with mCRPC must have measurable prostate specific antigen above normal limits (per local ranges)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Normotensive or well controlled blood pressure, with or without current antihypertensive treatment
- Females of child-bearing potential must use 2 highly effective methods of contraception
- Male patients should be willing to use barrier contraception
- Any investigational medicinal product or other systemic anticancer treatment within at least 4 weeks prior to the first dose of study treatment, or within 8 weeks after immunotherapy or other long half-life antibody therapy, whichever is the most appropriate and as judged by the Investigator
- Evidence of recent or significant cardiovascular disease
- Unresolved toxicities from prior therapy greater than CTCAE Grade 1 at starting study treatment
- History of seizures, CNS tumors or CNS metastasis
- Active or prior documented autoimmune or inflammatory disorders within the past 3 years to the start of treatment
- Patients with prior Grade3 immune-mediated reactions or more
- Evidence of severe or uncontrolled systemic diseases
- Inadequate bone marrow reserve or organ function
- Refractory nausea and vomiting, chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of AZD4635
- History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or class to AZD4635
- Judgment by the Investigator that the patient should not participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>-
- Secondary Outcome Measures
Name Time Method efficacy<br>pharmacodynamics<br>-